{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:47:34Z","timestamp":1771951654589,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bcp.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T14:04:41Z","timestamp":1441634681000},"page":"231-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy"],"prefix":"10.1016","volume":"98","author":[{"given":"Samar F.","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesam M.","family":"El-Bakly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem N.","family":"El-Naga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azza S.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebtehal","family":"El-Demerdash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.09.001_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11894-009-0080-9","article-title":"Antifibrotic therapies: will we ever get there?","volume":"12","author":"Thompson","year":"2010","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.bcp.2015.09.001_bib0010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0002-9343(70)80135-8","article-title":"Hepatic fibrosis. Correlation of biochemical and morphologic investigations","volume":"49","author":"Popper","year":"1970","journal-title":"Am. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2015.09.001_bib0015","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1186\/1755-1536-5-S1-S26","article-title":"Reversibility of liver fibrosis","volume":"5","author":"Pellicoro","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.bcp.2015.09.001_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-10-40","article-title":"Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)","volume":"10","author":"Poynard","year":"2010","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1148\/radiol.10091295","article-title":"Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT","volume":"256","author":"Ronot","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0030","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/alcalc\/35.3.286","article-title":"Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients","volume":"35","author":"Khan","year":"2000","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1517\/14656566.2012.653341","article-title":"Treatment failure with new hepatitis C drugs","volume":"13","author":"Soriano","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bcp.2015.09.001_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2015.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3748\/wjg.v21.i6.1994","article-title":"Retreatment with peginterferon and ribavirin in chronic hepatitis C","volume":"21","author":"Jo","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.12998\/wjcc.v3.i3.210","article-title":"Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6","volume":"3","author":"Papastergiou","year":"2015","journal-title":"World J. Clin. Cases"},{"key":"10.1016\/j.bcp.2015.09.001_bib0055","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/prca.201000049","article-title":"Hepatitis C virus-induced oxidative stress and mitochondrial dysfunction: a focus on recent advances in proteomics","volume":"4","author":"Simula","year":"2010","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.bcp.2015.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1440-1746.2006.04759.x","article-title":"Hepatic iron accumulation is associated with disease progression and resistance to interferon\/ribavirin combination therapy in chronic hepatitis C","volume":"22","author":"Fujita","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.22486","article-title":"Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity","volume":"48","author":"Miura","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0070","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2007.10.011","article-title":"Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription","volume":"134","author":"Nishina","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3748\/wjg.v16.i14.1747","article-title":"Successful antiviral therapy is associated with a decrease of serum prohepcidin in chronic hepatitis C","volume":"16","author":"Jaroszewicz","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0080","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.26656","article-title":"Hepcidin as a predictor of treatment response in chronic hepatitis C infection","volume":"59","author":"Strnad","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mehy.2011.10.011","article-title":"Inhibition of translation initiation factors might be the potential therapeutic targets for HCV patients with hepatic iron overload","volume":"78","author":"Liu","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bcp.2015.09.001_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0741-8329(03)00101-0","article-title":"Iron chelators and iron toxicity","volume":"30","author":"Brittenham","year":"2003","journal-title":"Alcohol"},{"key":"10.1016\/j.bcp.2015.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.4155\/fmc.09.121","article-title":"Synthetic and natural iron chelators: therapeutic potential and clinical use","volume":"1","author":"Hatcher","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bcp.2015.09.001_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00365529509093237","article-title":"Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine","volume":"30","author":"Sakaida","year":"1995","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-4274(99)00021-1","article-title":"Deferoxamine delays the development of the hepatotoxicity of acetaminophen in mice","volume":"106","author":"Schnellmann","year":"1999","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bcp.2015.09.001_bib0110","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1097\/01.CCM.0000142699.54266.D9","article-title":"Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats","volume":"32","author":"Ritter","year":"2004","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.bcp.2015.09.001_bib0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00535-007-2020-5","article-title":"The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis","volume":"42","author":"Jin","year":"2007","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2893.1996.tb00003.x","article-title":"The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B","volume":"3","author":"Bayraktar","year":"1996","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.bcp.2015.09.001_bib0125","doi-asserted-by":"crossref","first-page":"G729","DOI":"10.1152\/ajpgi.00013.2011","article-title":"Animal models for the study of liver fibrosis: new insights from knockout mouse models","volume":"300","author":"Hayashi","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0009-9120(96)00003-6","article-title":"A simplified method for the analysis of hydroxyproline in biological tissues","volume":"29","author":"Reddy","year":"1996","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.bcp.2015.09.001_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3748\/wjg.v18.i2.119","article-title":"Immune mechanisms of Concanavalin A model of autoimmune hepatitis","volume":"18","author":"Wang","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0140","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.3748\/wjg.15.4499","article-title":"Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells","volume":"15","author":"Hou","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchromb.2010.12.030","article-title":"Purification of a lectin from Canavalia ensiformis using PEG-citrate aqueous two-phase system","volume":"879","author":"Soares","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bcp.2015.09.001_bib0150","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jaut.2009.08.006","article-title":"CD4 T cells in hepatic immune tolerance","volume":"34","author":"Carambia","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2015.09.001_bib0155","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/intimm\/11.9.1491","article-title":"Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A","volume":"11","author":"Kimura","year":"1999","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0160","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.510310218","article-title":"Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis","volume":"31","author":"Louis","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0165","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1478-3231.2008.01841.x","article-title":"Endogenous alpha-calcitonin gene-related peptide mitigates liver fibrosis in chronic hepatitis induced by repeated administration of concanavalin A","volume":"29","author":"Kamiyoshi","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.bcp.2015.09.001_bib0170","doi-asserted-by":"crossref","first-page":"e82232","DOI":"10.1371\/journal.pone.0082232","article-title":"Preventive effect of halofuginone on concanavalin A-induced liver fibrosis","volume":"8","author":"Liang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.09.001_bib0175","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1139\/cjpp-2014-0085","article-title":"Hepatoprotective effects of early pentoxifylline administration on hepatic injury induced by concanavalin A in rat","volume":"92","author":"Mohamed","year":"2014","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0180","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/labinvest.2008.105","article-title":"Stearoyl-CoA desaturase 1 deficiency protects mice from immune-mediated liver injury","volume":"89","author":"Feng","year":"2009","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bcp.2015.09.001_bib0185","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.09.001_bib0190","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jhep.2010.11.035","article-title":"Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib","volume":"55","author":"Liu","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cbf.1082","article-title":"Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair","volume":"22","author":"Ali","year":"2004","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.bcp.2015.09.001_bib0200","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1590\/1414-431X20143704","article-title":"Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A","volume":"47","author":"Wan","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bcp.2015.09.001_bib0205","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/sji.12144","article-title":"The effect of antifibrotic drug halofugine on Th17 cells in concanavalin A-induced liver fibrosis","volume":"79","author":"Liang","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0210","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/j.gastro.2011.06.065","article-title":"Improvement in liver pathology of patients with beta-thalassemia treated with deferasirox for at least 3 years","volume":"141","author":"Deugnier","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0215","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/jgh.12720","article-title":"Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox","volume":"30","author":"Sobbe","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00210-011-0685-z","article-title":"Protective effect of andrographolide against concanavalin A-induced liver injury","volume":"385","author":"Shi","year":"2012","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0225","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-2006-927397","article-title":"Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury","volume":"45","author":"Tiegs","year":"2007","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0230","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/hep.510230403","article-title":"Induction of interleukin-6 by interferon alfa and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C","volume":"23","author":"Ito","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0235","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.thj.6200565","article-title":"Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells","volume":"5","author":"Usui","year":"2004","journal-title":"Hematol. J."},{"key":"10.1016\/j.bcp.2015.09.001_bib0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaut.2009.08.003","article-title":"Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration","volume":"34","author":"Drucker","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2015.09.001_bib0245","first-page":"290","article-title":"Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling","volume":"2011","author":"Malchow","year":"1812","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2015.09.001_bib0250","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3851\/IMP1864","article-title":"Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-alpha2b plus ribavirin","volume":"16","author":"Ueyama","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bcp.2015.09.001_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2006.00772.x","article-title":"Hepcidin-central regulator of iron metabolism","volume":"78","author":"Atanasiu","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0260","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.pathol.4.110807.092205","article-title":"Regulation of hepcidin and iron-overload disease","volume":"4","author":"Lee","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bcp.2015.09.001_bib0265","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2119\/2006-00057.Fujita","article-title":"Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C","volume":"13","author":"Fujita","year":"2007","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2015.09.001_bib0270","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2893.2009.01244.x","article-title":"Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C","volume":"17","author":"Tsochatzis","year":"2010","journal-title":"J. Viral. Hepat."},{"key":"10.1016\/j.bcp.2015.09.001_bib0275","doi-asserted-by":"crossref","first-page":"e46631","DOI":"10.1371\/journal.pone.0046631","article-title":"Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.09.001_bib0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.25666","article-title":"Pegylated interferon-alpha induced hypoferremia is associated with the immediate response to treatment in hepatitis C","volume":"56","author":"Ryan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2015.09.001_bib0285","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2002-11-3610","article-title":"Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron","volume":"102","author":"Gehrke","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.09.001_bib0290","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3748\/wjg.v19.i19.2921","article-title":"Inhibiting heme oxygenase-1 attenuates rat liver fibrosis by removing iron accumulation","volume":"19","author":"Wang","year":"2013","journal-title":"World J. Gastroenterol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215005742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215005742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T03:31:59Z","timestamp":1567135919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215005742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0006295215005742"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.09.001","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}